Table 2.
Cytology, WFA-sialylated MUC1 and CA19-9 levels in the bile samples of the study patients
| Characteristics | Benign biliary disease (n = 115) |
Total (n = 183) |
Perihilar CC (n = 95) |
Distal CC (n = 50) |
Gallbladder carcinoma (n = 28) |
Intrahepatic CC (n = 10) |
|---|---|---|---|---|---|---|
| Cytology, n (%) | ||||||
| Negative | 46 (40.0) | 48 (26.2) | 28 (29.5) | 11 (22.0) | 6 (21.4) | 3 (30.0) |
| Positive suggestive | 5 (4.3) | 64 (35.0) | 36 (37.9) | 19 (38.0) | 8 (28.6) | 1 (10.0) |
| Positive | 0 (0) | 28 (15.3) | 8 (8.4) | 14 (28.0) | 5 (17.9) | 1 (10.0) |
| None | 64 (55.7) | 43 (23.5) | 23 (24.2) | 6 (12.0) | 9 (32.1) | 5 (50.0) |
| WFA-sialylated MUC1 (nL/µg protein)* |
7.4 (0.3–45) |
27 (10–653)a |
24 (10–653)a |
29 (10–533)a |
25 (11–341)a |
60 (25–432)a |
| CA19-9 (U/µg protein)* | 1038 (0.1–11389) |
3372 (0.1–50156)a |
3468 (0.1–32149)a |
2484 (3.5–48807) |
3091 (48–17257) |
4819 (102–50156)a |
Values are expressed as medians (range)
Total represents the sum of cases with intrahepatic CC, perihilar CC, distal CC, and gallbladder carcinoma
CC cholangiocarcinoma, WFA Wisteria floribunda agglutinin, MUC1 mucin core polypeptide 1, CA19-9 carbohydrate antigen 19-9
*Adjusted by biliary protein concentration
a significantly different from benign biliary disease